ArticleEClinicalMedicine2023

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022.

Xingxian Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.